CLIA Kit for Angiotensinogen (AGT) Homo sapiens (Human) Sandwich CLIA

ANHU; SERPINA8; Angiotensin; Renin Substrate; Serpin Peptidase Inhibitor,Clade A,Member 8(Alpha-1 Antiproteinase,Antitrypsin)

  • UOM
    1. 48T
    2. 96T
    3. 96T*5
    4. 96T*10
    5. 96T*100
  • FOB US$ 588.00 US$ 840.00 US$ 3,780.00 US$ 7,140.00 US$ 58,800.00
  • Quantity
    Out of stock
Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Angiotensinogen (AGT) Packages (Simulation)
  • CLIA Kit for Angiotensinogen (AGT) Packages (Simulation)
  • CLIA Kit for Angiotensinogen (AGT) Results demonstration
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Angiotensinogen (AGT) and the recovery rates were calculated by comparing the measured value to the expected amount of Angiotensinogen (AGT) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 83-97 90
EDTA plasma(n=5) 84-98 90
heparin plasma(n=5) 98-105 102

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Angiotensinogen (AGT) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Angiotensinogen (AGT) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Angiotensinogen (AGT) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 82-103% 88-98% 96-105% 94-104%
EDTA plasma(n=5) 92-103% 97-105% 95-102% 89-98%
heparin plasma(n=5) 80-97% 91-98% 99-105% 84-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Angiotensinogen (AGT)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Angiotensinogen (AGT). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Angiotensinogen (AGT). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Angiotensinogen (AGT) level in the sample or standard.;

Citations

  • Elevated urinary angiotensinogen a marker of intrarenal renin angiotensin system in hypertensive renal transplant recipients: does it play a role in development of proteinuria in hypertensive renal transplant patients?Wiley: source
  • The relation between urinary angiotensinogen and proteinuria in renal AA amyloidosis patientsPubMed: 22320202
  • Urinary angiotensinogen as a marker of intrarenal angiotensin II activity in adolescents with primary hypertensionPubMed: PMC3661928
  • Urinary angiotensinogen as a novel marker of obstructive nephropathy in childrenPubmed: 23772991
  • Association between urinary angiotensinogen, hypertension and proteinuria in pregnant women with preeclampsiaSagepub: Source
  • MP707 CHARACTERISTICS AND OUTCOMES OF CHILDREN WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE COHORT FROM THE ESPN/ERA-EDTA REGISTRYOxfordjournals:Source
  • Relationship between blood pressure varPubMed: 26223347
  • Higher Serum Angiotensinogen Is an Indicator of IgA Vasculitis with Nephritis Revealed by Comparative Proteomes AnalysisPubMed: 26098644
  • Korelasi pengukuran antropometri dengan tekanan darah dan angiotensinogen plasma pada dewasaIndex.Php: Art
  • Relationship between blood pressure variability and renal activity of the renin-angiotensin system.pubmed:26223347
  • Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.pubmed:27890915

Recommend products